Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells
- PMID: 14559802
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells
Retraction in
-
Retraction: Effects of Oligonucleotide N3'→P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells.Cancer Res. 2024 Mar 15;84(6):937. doi: 10.1158/0008-5472.CAN-24-0518. Cancer Res. 2024. PMID: 38486483 No abstract available.
Abstract
Telomeres are specialized nucleoprotein complexes that protect against fusion and degradation of linear chromosomes. Critical shortening of telomeres leads to irreversible cessation of cell division, whereas telomerase elongates telomere sequences to compensate for losses that occur with each round of DNA replication. Continued proliferation of tumor cells requires this enzyme to maintain chromosomal stability and to counteract the cellular mitotic clock. In this study, we evaluated the effect of oligonucleotide N3'-->P5' thio-phosphoramidate (NP), which targets template RNA component, in human multiple myeloma (MM) cell lines and patient MM cells. Fluorescein staining at 24 h confirmed NP uptake in 84.7 and 86.1% of MM.1S cells and MM patient cells, respectively, without any transfection enhancer. High transfection efficiency was observed into both CD138(+) and CD138(-) MM patient cells. Match NP (7S), but not mismatch NP (30S), inhibited telomerase activity in MM.1S cells, U266 cells, and RPMI 8226 cells, as well as in patient MM cells. Moreover, 7S inhibited cytokine-induced telomerase activity in MM.1S cells. 7S treatment-induced progressive telomere shortening was associated with growth inhibition and cell death in MM.1S cells with short telomeres (2.5 kb), but not in U266 cells with long telomeres (9.0 kb), at 56 days of culture. Progressive telomere shortening leading to growth inhibition and cell death in MM.1S cells was associated with up-regulation of p21 and phosphorylation of p53 (Ser-15). These studies, therefore, identify the molecular sequelae of NP oligonucleotide (GRN163) against human telomerase RNA component as a telomerase inhibitor and provide the rationale for the development of telomerase-targeted therapies to improve patient outcome in MM.
Similar articles
-
Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.Oncogene. 2002 Jan 21;21(4):638-42. doi: 10.1038/sj.onc.1205064. Oncogene. 2002. PMID: 11850790
-
A novel telomerase template antagonist (GRN163) as a potential anticancer agent.Cancer Res. 2003 Jul 15;63(14):3931-9. Cancer Res. 2003. PMID: 12873987
-
Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma.Blood. 2004 Jan 1;103(1):258-66. doi: 10.1182/blood-2003-02-0546. Epub 2003 Sep 11. Blood. 2004. PMID: 12969977
-
Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.Chem Biodivers. 2010 Mar;7(3):477-93. doi: 10.1002/cbdv.200900187. Chem Biodivers. 2010. PMID: 20232321 Review.
-
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.Anticancer Drugs. 2008 Apr;19(4):329-38. doi: 10.1097/CAD.0b013e3282f5d4c2. Anticancer Drugs. 2008. PMID: 18454043 Review.
Cited by
-
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.Oncogene. 2014 Mar 20;33(12):1495-505. doi: 10.1038/onc.2013.103. Epub 2013 Apr 22. Oncogene. 2014. PMID: 23604115 Free PMC article.
-
New prospects for targeting telomerase beyond the telomere.Nat Rev Cancer. 2016 Aug;16(8):508-24. doi: 10.1038/nrc.2016.55. Epub 2016 Jun 24. Nat Rev Cancer. 2016. PMID: 27339602 Review.
-
Targeting human telomerase for cancer therapeutics.Cytotechnology. 2004 Jun;45(1-2):75-90. doi: 10.1007/s10616-004-5127-z. Cytotechnology. 2004. PMID: 19003245 Free PMC article.
-
The CINs of Polo-Like Kinase 1 in Cancer.Cancers (Basel). 2020 Oct 13;12(10):2953. doi: 10.3390/cancers12102953. Cancers (Basel). 2020. PMID: 33066048 Free PMC article. Review.
-
New frontiers in the treatment of multiple myeloma.ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous